Articles tagged with "U.S. Food and Drug Administration (FDA)"

FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR

March 14, 2023 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Abaloparatide to Treat Men with Osteoporosis & a High Risk of Fracture

February 15, 2023 • By Michele B. Kaufman, PharmD, BCGP

FDA Revokes Emergency Use Authorization for Evusheld

February 2, 2023 • By From the College

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

January 31, 2023 • By Michele B. Kaufman, PharmD, BCGP

Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia

December 12, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Ustekinumab for Children with PsA

November 7, 2022 • By Michele B. Kaufman, PharmD, BCGP

Belimumab Promising for Children with Lupus Nephritis

October 6, 2022 • By Michele B. Kaufman, PharmD, BCGP

An Evidence-Based Drug Update & Guidance for Rheumatologists

August 14, 2022 • By Samantha C. Shapiro, MD

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

July 13, 2022 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Risankizumab-rzaa for PsA

April 20, 2022 • By Michele B. Kaufman, PharmD, BCGP

1
2
3
…
12
Next Page »